Anhui Hua Ren Health Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Anhui Zheng Yao Pharmaceutical Technology Co., Ltd., has received a drug registration acceptance notice from the NMPA for Ferrous Succinate Tablets. This signifies the product has entered the review phase. The company anticipates no significant short-term impact on performance, advising investors to exercise caution.
Summary generated by AI · Always verify with source document
Securities Code: 301408
Securities Abbreviation: Hua Ren Health
Announcement No.: 2026-038
Anhui Hua Ren Health Pharmaceutical Co., Ltd.
Announcement on Wholly-Owned Subsidiary Receiving Drug Registration Acceptance Notice
The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.